Market Outlook

Bys expected to reach approximately USD 53.41 billion, expanding at a CAGR of 7.20% during the forecast period 2026–2035. The market is estimated at USD 26.65 billion in 2025, with the historical period covering 2021–2024. Values in this report are expressed in USD billions.

For this report, the market is defined specifically around recurring in vitro diagnostic test consumables, including diagnostic reagents, assay kits, molecular test cartridges, rapid diagnostic cassettes, test strips, multi-analyte panels, specialty diagnostic kits, and self-testing products used to detect, screen, characterize, or monitor disease from specimens collected from the human body. Standalone laboratory analyzers, software-only products, and laboratory testing services are excluded to prevent inflation of the test-kit opportunity with the broader U.S. IVD systems market.

The market’s historical trajectory is unusual because COVID-19 created a temporary volume and revenue distortion. U.S. IVD test-kit revenue is estimated at approximately USD 29.75 billion in 2021 and USD 31.20 billion in 2022, when molecular PCR reagents, antigen tests, respiratory panels, and home testing kits operated at exceptional volumes. Revenue normalized to approximately USD 27.05 billion in 2023 and USD 25.58 billion in 2024 as pandemic-specific demand contracted. The return to approximately USD 26.65 billion in 2025 marks a transition from emergency-driven testing toward structurally durable growth led by molecular diagnostics, oncology, cardiometabolic monitoring, sexual health, respiratory multiplexing, women’s health, decentralized testing, and home sample collection.

The fundamental demand base remains exceptionally large. Approximately 14 billion laboratory tests are performed annually in the United States across more than 266,000 CLIA-certified laboratories. Laboratory information influences a substantial proportion of clinical decisions, making recurring test consumables integral to nearly every major episode of care. Unlike diagnostic instruments, which follow multi-year capital replacement cycles, test kits generate recurring revenue every time a specimen is processed. This gives the category a particularly attractive installed-base economic model.

Demand is also moving toward tests that can answer more clinically relevant questions from fewer samples. Multiplex respiratory panels, syndromic infectious-disease panels, HPV genotyping, cancer-associated molecular assays, companion diagnostics, high-sensitivity cardiac biomarkers, HbA1c testing, molecular STI panels, antimicrobial resistance testing, and stool-based colorectal cancer screening are increasing the economic value of each testing episode.

The U.S. IVD test kits industry will therefore be shaped less by raw test counts alone and increasingly by revenue per actionable result. Hospitals, laboratories, physician practices, payers, and patients are favoring tests that shorten time to diagnosis, reduce repeat visits, permit treatment initiation during the same encounter, support targeted therapy, or move testing into lower-cost settings.

The forecast implies an estimated market value of approximately USD 28.57 billion in 2026, USD 30.63 billion in 2027, USD 32.83 billion in 2028, USD 35.19 billion in 2029, USD 37.73 billion in 2030, and USD 53.41 billion by 2035. Growth will not be uniform. Molecular, oncology, multiplex, self-collection, and decentralized testing formats are expected to outpace mature routine chemistry and conventional single-analyte testing.

 

Introduction

According to the U.S. IVD Test Kits Market Report, the United States represents one of the world’s most commercially important diagnostic testing environments because it combines a population of approximately 341.8 million people in 2025, a large aging population, extensive insurance coverage, high chronic disease prevalence, advanced laboratory infrastructure, sophisticated hospital systems, and strong acceptance of new diagnostic technologies.

Nearly 18.9% of the U.S. population is aged 65 years or older, creating a structurally expanding testing pool for diabetes, cardiovascular conditions, renal disease, cancer, endocrine disorders, infections, coagulation abnormalities, and medication monitoring. Older adults generally generate substantially higher healthcare utilization than younger populations, supporting recurring demand across chemistry, immunoassay, hematology, microbiology, and molecular diagnostics.

IVD test kits sit at the intersection of multiple U.S. healthcare economics. For laboratories, the critical measures are cost per reportable result, throughput, reagent utilization, quality-control burden, labor requirements, reimbursement, and analyzer uptime. For hospitals, diagnostic value is increasingly evaluated according to its effect on emergency-department throughput, antimicrobial stewardship, admission decisions, length of stay, isolation utilization, and treatment selection. Physician practices and urgent-care centers place greater emphasis on simplicity, CLIA-waived workflows, fast turnaround, low hands-on time, and the ability to make decisions before the patient leaves.

Consumer expectations are creating another layer of market change. COVID-19 normalized self-testing among millions of Americans and demonstrated that patients can collect specimens, run lateral-flow assays, interpret results, and participate directly in diagnostic workflows. The next commercial phase extends beyond single-pathogen COVID testing toward combined respiratory tests, reproductive health, cervical cancer screening through self-collection, sexually transmitted infection testing, gastrointestinal screening, and chronic disease monitoring.

At the same time, laboratory economics remain constrained. Medicare clinical laboratory payments, commercial payer negotiations, labor shortages, reagent costs, and increasing quality requirements mean that a technically superior assay does not automatically achieve commercial adoption. Manufacturers must demonstrate that incremental test cost is supported by better clinical decisions, improved labor productivity, higher throughput, fewer downstream procedures, reduced unnecessary treatment, or access to a reimbursable clinical pathway.

The result is a market that rewards both clinical innovation and workflow economics. The strongest products through 2035 will be kits that combine analytical performance with simple sample preparation, automation compatibility, fast turnaround, multi-analyte capability, scalable manufacturing, reliable supply, reimbursement support, and clear clinical utility.

 

Key Market Drivers: What’s Fueling the U.S. IVD Test Kits Market Boom?

The most durable driver is the extraordinary volume of diagnostic testing embedded in U.S. healthcare. With approximately 14 billion laboratory tests performed annually, even modest shifts toward higher-value molecular or multiplex technologies can translate into significant market expansion. Every emergency visit, inpatient admission, surgery, pregnancy, cancer workup, chronic disease review, infectious-disease investigation, and preventive screening program creates potential demand for IVD consumables.

Chronic disease prevalence is another major structural driver. Approximately 38.4 million Americans have diabetes, representing around 11.6% of the population, while an estimated 97.6 million U.S. adults have prediabetes. Diabetes alone creates sustained utilization of glucose, HbA1c, renal-function, lipid, liver-function, ketone, and related metabolic assays. Because these conditions require repeated measurement rather than one-time diagnosis, they generate recurring kit demand independent of economic cycles.

Cancer diagnostics are becoming an increasingly important value-growth engine. Approximately 2.04 million new cancer cases were expected to be diagnosed in the United States in 2025, with more than 618,000 cancer deaths estimated for the year. Cancer testing is expanding beyond pathology and imaging into molecular characterization, hereditary-risk assessment, therapy selection, minimal residual disease evaluation, companion diagnostics, and non-invasive screening. The commercial opportunity therefore increasingly depends on the clinical value of individual tests rather than simply specimen volume.

Infectious-disease testing remains a major demand pool even after COVID normalization. U.S. public-health data recorded more than 2.2 million reported cases of chlamydia, gonorrhea, and syphilis in 2024. More than 38,000 people received an HIV diagnosis in 2024, while the 2024–2025 influenza season produced an estimated 51 million illnesses, 23 million medical visits, 710,000 hospitalizations, and 45,000 deaths. These numbers support sustained demand for rapid antigen assays, molecular respiratory testing, STI panels, HIV diagnostics, hepatitis assays, gastrointestinal panels, and antimicrobial resistance testing.

A second major driver is decentralization of testing. Hospital laboratories remain critical, but test consumption is spreading into emergency departments, physician offices, urgent-care clinics, retail clinics, pharmacies, substance-use treatment centers, correctional facilities, community health centers, and homes. Testing that previously required a central laboratory can increasingly be performed near the patient through cartridge-based molecular systems, lateral-flow technologies, compact immunoassay platforms, and simplified specimen collection.

This decentralization changes the purchasing criteria. Central laboratories emphasize cost per test and throughput. Decentralized users emphasize simplicity, speed, reliability, minimal calibration, room-temperature storage, waived status where applicable, and limited operator training. Manufacturers able to engineer sophisticated analytical performance into low-complexity workflows can access larger user populations.

A third driver is the increasing clinical adoption of molecular testing. Molecular diagnostics represented roughly one-quarter of the broader U.S. IVD market around 2025 and are growing faster than many legacy modalities. PCR remains the core platform, but growth is expanding into multiplex amplification, digital PCR, targeted sequencing, genotyping, syndromic panels, and molecular screening. The economics are attractive because molecular kits generally command higher revenue per test than conventional chemistry products while providing information that can materially change clinical management.

A fourth driver is the shift from single-analyte testing to multiplex and syndromic testing. A patient presenting with respiratory symptoms may have influenza A, influenza B, SARS-CoV-2, RSV, or another pathogen. Testing pathogens sequentially delays clinical decisions and consumes labor. Multi-analyte kits can reduce diagnostic uncertainty within one workflow. Similar dynamics are visible in gastrointestinal infections, bloodstream infections, meningitis and encephalitis, sexual health, and antimicrobial resistance.

A fifth driver is screening expansion. Colorectal cancer screening beginning at younger ages, cervical cancer screening, HPV testing, prenatal diagnostics, newborn screening, diabetes screening, lipid testing, and other preventive pathways create opportunities to identify patients before advanced disease develops. Diagnostic manufacturers benefit when testing becomes embedded into guideline-driven screening rather than being ordered only after symptoms occur.

Finally, U.S. reimbursement remains an essential demand determinant. Medicare’s Clinical Laboratory Fee Schedule contains thousands of test records and strongly influences commercial laboratory economics. There is no phase-in payment reduction for applicable clinical diagnostic laboratory tests in 2026, although payment reductions based on updated private-payer data can resume beginning in 2027 subject to statutory limits. Manufacturers must therefore develop assays with reimbursement durability and strong health-economic arguments, particularly when targeting high-cost molecular technologies.

 

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation is moving the U.S. IVD test kits market from the traditional objective of detecting an analyte toward a broader objective: delivering the right clinical decision at the right location with the least possible workflow friction.

One of the clearest changes is the rise of single-visit molecular diagnosis. In 2024, the first point-of-care hepatitis C RNA test received U.S. marketing authorization, allowing appropriately certified decentralized sites to detect HCV RNA from fingerstick blood and provide results in approximately one hour. The strategic importance extends beyond hepatitis C. It demonstrates how molecular diagnostics can move from central laboratories into settings where immediate diagnosis can directly support treatment initiation and reduce loss to follow-up.

Respiratory testing is undergoing a similar transition. During the pandemic, consumers became familiar with rapid antigen testing, but the next competitive cycle centers on multi-analyte products capable of differentiating influenza A, influenza B, COVID-19, and increasingly RSV from a single specimen. Traditional marketing authorizations for combined respiratory tests are gradually moving the market beyond temporary emergency-use frameworks and creating a durable consumer and professional testing category.

Self-collection is another major innovation frontier. U.S. approvals allowing vaginal specimens to be self-collected for high-risk HPV testing represent a meaningful shift in cervical cancer screening. Self-collection can lower procedural barriers for patients who are overdue for screening, have limited access to gynecologic services, or prefer a less invasive collection process. Subsequent progress toward home collection and transport further expands the potential reach of molecular screening.

Oncology diagnostics are moving toward non-invasive and molecularly enriched formats. The approval of the next-generation Cologuard Plus test in 2024 illustrates how stool collection kits, molecular biomarkers, and centralized analysis can be integrated into a population-scale cancer screening pathway. Similar innovation is occurring across liquid biopsy, inherited cancer risk, tumor profiling, therapy selection, and monitoring.

Manufacturers are also raising the bar through multiplexing. Historically, increasing the number of targets frequently required more instruments, additional laboratory steps, or larger sample volumes. New assay designs are enabling multiple pathogens, biomarkers, or genetic targets to be evaluated from a single specimen. This improves clinical information density and can increase the revenue opportunity per cartridge or panel.

Microfluidics and cartridge engineering are equally important. Sample preparation has traditionally been one of the largest barriers to decentralized molecular testing. Closed cartridges that automate extraction, amplification, detection, and interpretation reduce operator dependence and contamination risk. The commercial advantage is significant because simplified workflows expand the addressable market beyond high-complexity laboratories.

Artificial intelligence is emerging indirectly within test kits through interpretation systems and laboratory software. AI does not replace the reagent chemistry, but it can improve signal interpretation, identify quality-control anomalies, prioritize abnormal results, support digital morphology, or integrate multiple biomarkers into clinical risk scores. The test kit increasingly becomes one component of a broader diagnostic decision system.

Innovation must also address manufacturing resilience. The pandemic exposed the strategic importance of swabs, membranes, plastics, enzymes, primers, antibodies, controls, transport media, packaging materials, and specialty chemicals. Health systems and distributors now place greater value on dual sourcing, domestic capacity, shelf-life extension, predictable allocation, and manufacturing scalability. Companies able to maintain supply during seasonal infectious-disease spikes can gain market share even without changing the underlying assay.

Quality systems are also entering a new operating environment. The FDA’s Quality Management System Regulation became effective in February 2026, incorporating ISO 13485:2016 into U.S. device quality-system requirements. For IVD kit manufacturers, this increases the strategic importance of supplier controls, design history, manufacturing validation, complaint handling, quality audits, and lifecycle documentation.

 

Segmentation Insights

The U.S. IVD Test Kits Market is segmented by product format, technology, application, sample type, and end user.

 

By Product Format

Reagent and Assay Kits

Reagent and assay kits represent the largest recurring revenue pool because they are consumed continuously on installed diagnostic analyzers. The category includes chemistry reagents, immunoassay packs, hematology reagents, coagulation assays, microbiology reagents, calibrators, controls, and specialty diagnostic consumables. Large hospital and reference laboratories favor high-throughput reagent systems because automation reduces labor cost per reportable result.

Molecular Cartridges and Closed-System Kits

Molecular cartridges represent one of the strongest value-growth categories. These products combine extraction, amplification, and detection chemistry within standardized kits used on dedicated PCR or molecular platforms. Infectious-disease testing dominates current volume, but oncology, sexual health, women’s health, transplantation, pharmacogenomics, and genetic testing continue to expand the addressable market.

Rapid Cassette and Lateral-Flow Kits

Rapid diagnostic cassettes remain commercially important because they provide low-cost and low-complexity testing for respiratory infections, pregnancy, infectious diseases, cardiac markers, drugs of abuse, and other applications. COVID-19 dramatically expanded manufacturing capacity and consumer familiarity with lateral-flow formats. The next growth stage will depend on multiplex capabilities and improved analytical sensitivity.

Test Strips and Dipstick-Based Kits

Test strips maintain large recurring volume in glucose monitoring, urinalysis, ketone testing, pregnancy testing, fecal occult blood applications, and other routine diagnostics. Unit prices are lower than molecular cartridges, but enormous testing frequency supports attractive market scale. Convenience and established distribution channels protect these categories from rapid displacement.

Self-Test and Integrated Home Kits

Self-testing represents the most disruptive product format. The category includes fully performed home tests as well as collection kits that allow specimens to be shipped to laboratories. Consumer adoption will depend on accuracy, simplicity, privacy, digital result support, insurance coverage, and clear pathways for follow-up. Respiratory disease and reproductive health are leading the transition, while cancer screening and sexual health provide substantial longer-term opportunity.

 

By Technology

Immunoassay

Immunoassays remain one of the largest technology categories in U.S. IVD test kits. Chemiluminescent, fluorescent, enzyme-linked, and lateral-flow immunoassays support testing for hormones, infectious diseases, cardiac biomarkers, cancer markers, thyroid disorders, fertility, allergies, autoimmune diseases, and therapeutic monitoring. Mature high-volume demand gives this segment strong recurring revenue despite price pressure.

Molecular Diagnostics

Molecular diagnostic kits are expected to deliver the strongest sustained value growth. PCR, RT-PCR, isothermal amplification, digital PCR, and targeted nucleic-acid testing provide high sensitivity and specificity across infectious diseases, cancer, inherited disorders, transplantation, reproductive health, and precision medicine. Multiplex molecular cartridges are particularly attractive because they reduce time-to-answer while supporting higher revenue per patient.

Clinical Chemistry

Clinical chemistry test kits form a high-volume foundation of U.S. laboratory medicine. Glucose, electrolytes, renal-function markers, liver enzymes, lipid panels, proteins, metabolites, and other routine assays are ordered across inpatient and outpatient care. Growth is comparatively mature, but recurring utilization remains enormous because chemistry testing is integral to chronic disease management and acute medical decision-making.

Hematology and Coagulation

Hematology and coagulation kits support complete blood counts, differential testing, coagulation measurement, thrombosis assessment, anticoagulation management, and related clinical workflows. Demand is tied to surgery, oncology, emergency medicine, cardiovascular care, pregnancy, infectious disease, and chronic disease management. Specialized coagulation and hematology assays provide more attractive growth than routine baseline tests.

Microbiology and Other Technologies

Culture media, identification reagents, antimicrobial susceptibility products, urinalysis kits, electrophoresis products, and other diagnostic technologies continue to form an important market layer. Microbiology is increasingly integrating conventional culture with molecular confirmation and rapid resistance detection, creating hybrid workflows rather than immediate replacement of established methods.

 

By Application

Infectious Diseases

Infectious diseases represent the largest application pool for U.S. IVD test kits. Respiratory viruses, STIs, HIV, hepatitis, urinary infections, gastrointestinal pathogens, bloodstream infections, healthcare-associated infections, and antimicrobial resistance collectively produce massive testing demand. The category is moving toward multiplex molecular panels and decentralized testing rather than returning to pre-pandemic diagnostic patterns.

Oncology

Oncology is expected to be among the fastest-growing applications through 2035. U.S. cancer incidence exceeding two million new cases annually supports demand for screening, diagnosis, tumor characterization, therapy selection, recurrence monitoring, and companion diagnostics. Molecular tests and biomarker-rich kits command substantially higher value than conventional single-analyte assays.

Diabetes and Cardiometabolic Disorders

Diabetes, lipid disorders, cardiovascular disease, renal disease, and metabolic abnormalities generate repeated testing throughout the patient journey. HbA1c, glucose, lipid, cardiac biomarker, kidney-function, and related assays have highly predictable recurring utilization. Point-of-care formats are particularly valuable because they allow treatment changes during the same clinical encounter.

Women’s Health, Reproductive Health, and Sexual Health

Pregnancy testing, fertility, prenatal screening, HPV testing, cervical cancer screening, vaginitis, chlamydia, gonorrhea, syphilis, and other reproductive-health applications create a large and increasingly decentralized market. Self-collection is likely to materially increase access and testing participation, particularly among populations that do not consistently engage with traditional clinic-based screening.

Endocrine, Autoimmune, Gastrointestinal, Renal, and Other Applications

The remaining market includes thyroid testing, autoimmune disease, allergy, gastrointestinal disorders, kidney disease, drug monitoring, toxicology, transplant testing, nutritional biomarkers, and other specialty applications. Many of these conditions require longitudinal laboratory measurement, supporting recurring kit consumption even when individual categories are smaller.

 

By Sample Type

Blood, Serum, and Plasma

Blood-derived specimens account for the largest share of test-kit utilization because they support chemistry, hematology, immunoassay, molecular diagnostics, coagulation, oncology, infectious disease, and therapeutic monitoring. The continued movement toward smaller sample volumes and fingerstick collection is expanding decentralized applications.

Respiratory Swabs and Saliva

Respiratory swabs became one of the most familiar specimen types during COVID-19 and remain central to influenza, COVID-19, RSV, streptococcal, and multiplex respiratory testing. Saliva-based workflows offer additional convenience, although clinical performance requirements remain application-specific.

Urine

Urine-based testing remains highly established in urinary tract assessment, pregnancy, drugs of abuse, kidney disease, sexually transmitted infections, diabetes-related monitoring, and general health screening. Dipsticks and rapid tests create high-volume demand, while molecular urine-based STI assays support premium growth.

Stool

Stool testing is gaining strategic importance through colorectal cancer screening, gastrointestinal pathogen panels, occult blood testing, inflammatory markers, and parasitology. Molecular and DNA-based screening are increasing the economic value of this specimen category.

Tissue, Cytology, and Other Specimens

Tissue, cervical cytology, vaginal specimens, cerebrospinal fluid, and other specialty samples support oncology, HPV testing, infectious diseases, neurological diagnostics, and precision medicine. Higher complexity generally limits testing volume but increases clinical value per result.

 

By End User

Hospital Laboratories

Hospital laboratories represent the largest single institutional user group. They support emergency, inpatient, surgical, oncology, infectious-disease, maternity, cardiovascular, and intensive-care testing. Procurement decisions increasingly consider total reagent cost, automation compatibility, labor utilization, turnaround time, analyzer consolidation, and supply reliability.

Independent and Reference Laboratories

Large independent laboratories process enormous routine and specialty testing volumes and therefore exert significant negotiating power over reagent suppliers. These organizations emphasize throughput, automation, logistics, assay menu breadth, and reagent economics. They are particularly influential in molecular diagnostics, oncology, genetics, women’s health, and high-volume routine testing.

Physician Offices, Urgent-Care Centers, and Retail Clinics

Decentralized clinical settings are among the fastest-expanding test-kit users. Respiratory tests, pregnancy testing, HbA1c, glucose, lipid testing, strep testing, STI assays, and other CLIA-waived products allow clinicians to make decisions within the same visit. Growth depends heavily on ease of use and reimbursement.

Public Health, Blood Banks, and Community Testing Programs

Public-health laboratories, blood centers, correctional facilities, substance-use treatment programs, community health centers, and similar organizations generate important demand for infectious-disease and screening kits. Products capable of reaching patients who might otherwise be lost to follow-up have particularly strong clinical value.

Home and Consumer Testing

The home represents a smaller but rapidly expanding end-user channel. Consumer purchasing behavior is now established for respiratory and reproductive-health testing. Continued regulatory expansion into home collection and multi-condition testing could make the consumer channel a material component of market growth through 2035.

 

Regional Insights: Where the Market is Growing Fastest

The U.S. IVD Test Kits Market is geographically segmented into the South, West, Northeast, and Midwest. Regional demand is influenced by population, demographic age, chronic disease prevalence, infectious-disease burden, health-system density, CLIA laboratory capacity, public-health infrastructure, academic medical centers, payer mix, and penetration of decentralized care.

The South is the largest regional market, while the West is expected to register the fastest long-term growth as molecular diagnostics, consumer testing, precision medicine, and technology-driven care models gain share.

South

The South represented an estimated USD 10.15 billion of U.S. IVD test-kit revenue in 2025 and is projected to approach USD 20.75 billion by 2035, implying approximately 7.4% annual growth.

The region comprises Alabama, Arkansas, Delaware, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West Virginia.

Texas is the most important individual Southern state market. Its population reached approximately 31.7 million in 2025, making it the second-largest state in the country. Houston, Dallas-Fort Worth, Austin, and San Antonio contain large hospital systems, specialty laboratories, cancer centers, academic institutions, urgent-care networks, and physician organizations. Texas therefore generates significant demand spanning routine chemistry, molecular infectious disease, oncology, women’s health, genetic testing, toxicology, and decentralized diagnostics.

Florida is another critical state, with approximately 23.5 million residents and one of the country’s largest older-adult populations. Its demographic structure creates intensive demand for diabetes testing, cardiovascular biomarkers, cancer screening, renal diagnostics, infectious-disease testing, and routine laboratory monitoring. Florida is also well positioned for expansion of home collection and consumer-oriented testing because of its large Medicare population and extensive outpatient care infrastructure.

Georgia and North Carolina exceeded approximately 11.3 million and 11.2 million residents, respectively, by 2025. Atlanta, Charlotte, Raleigh-Durham, and surrounding healthcare corridors support expanding hospital systems, reference laboratories, biotechnology organizations, and research activity. North Carolina’s life-sciences ecosystem also strengthens demand for molecular diagnostics and clinical-trial-related testing capabilities.

Tennessee, Virginia, and Maryland provide additional high-value opportunities through large health systems, academic centers, federal healthcare institutions, pathology networks, and growing metropolitan populations. Nashville’s healthcare-services concentration makes Tennessee strategically important for laboratory procurement decisions extending beyond the state’s population alone.

Alabama, Mississippi, Louisiana, Arkansas, Kentucky, Oklahoma, South Carolina, and West Virginia have significant chronic disease and rural healthcare burdens. These states create a different commercial requirement: manufacturers must combine central laboratory products for tertiary centers with rapid or decentralized kits capable of functioning in community hospitals and lower-resource environments.

The South is also strategically important for infectious-disease testing. More than half of U.S. HIV diagnoses continue to occur in the South, supporting ongoing demand for HIV screening and confirmatory testing alongside STI and viral hepatitis diagnostics. Population growth and persistent cardiometabolic disease burden are expected to keep the South the country’s largest IVD test-kit market throughout the forecast period.

West

The West accounted for an estimated USD 6.35 billion in 2025 and is projected to reach approximately USD 13.95 billion by 2035, representing an above-market CAGR of approximately 8.2%.

The region includes Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming.

California alone had approximately 39.36 million residents in 2025, making it the largest state market by population and one of the most important IVD innovation markets globally. The state’s combination of academic medical centers, integrated health systems, biotechnology companies, genomic laboratories, venture-backed diagnostics developers, and large managed-care organizations creates unusually favorable conditions for advanced molecular and precision diagnostics.

California is particularly influential in oncology, genomic testing, women’s health, transplant diagnostics, infectious disease, and digital integration. Large health systems can evaluate new testing models at scale, while technology-oriented consumers support adoption of home collection and digital diagnostic services.

Arizona and Nevada are important high-growth markets because of sustained population expansion and aging demographics. Both states are experiencing increasing demand for hospital, outpatient, and chronic disease testing. Phoenix, Tucson, Las Vegas, and Reno represent particularly important diagnostic demand centers.

Washington and Oregon have sophisticated integrated delivery networks and strong adoption of laboratory automation, molecular testing, and digitally connected care. Seattle’s life-sciences ecosystem strengthens Washington’s role in precision diagnostics and infectious-disease innovation.

Colorado and Utah have younger demographic profiles than several Eastern markets but combine population growth with strong hospital networks, biotechnology capabilities, and advanced outpatient infrastructure. These characteristics make them attractive markets for high-value molecular testing rather than only conventional routine assays.

Idaho, Montana, Wyoming, Alaska, Hawaii, and New Mexico are smaller revenue markets but illustrate why decentralized testing matters. Geographic distance and uneven specialist access create stronger clinical value for kits that shorten turnaround time and reduce the need to transport specimens to distant laboratories.

The West is expected to gain national market share through 2035 because the region aligns closely with the fastest-growing parts of IVD: molecular testing, genomics, precision oncology, consumer diagnostics, self-collection, and software-supported interpretation.

Northeast

The Northeast accounted for approximately USD 5.55 billion in 2025 and is expected to reach around USD 10.60 billion by 2035, representing approximately 6.7% annual growth.

The region comprises Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont.

New York is the region’s largest state market, with approximately 20.0 million residents in 2025. New York City and surrounding metropolitan areas have an exceptionally high concentration of hospitals, reference laboratories, academic institutions, cancer centers, and specialty medical practices. High patient density supports large routine testing volume, while the academic ecosystem accelerates adoption of molecular oncology, transplant testing, infectious-disease panels, and companion diagnostics.

Pennsylvania, with approximately 13.06 million residents, provides another large laboratory market centered around Philadelphia, Pittsburgh, and regional health systems. The state supports significant cancer diagnostics, cardiovascular testing, routine chemistry, pathology, and infectious-disease demand.

Massachusetts is strategically more important than population alone suggests. Boston’s concentration of academic medicine, biotechnology companies, genomic research organizations, and clinical trial infrastructure makes the state a leading early-adoption market for next-generation diagnostics.

New Jersey combines a dense patient population with major pharmaceutical, biotechnology, and laboratory operations. Its proximity to New York and Philadelphia further integrates the state into one of the most sophisticated diagnostic markets in the country.

Connecticut, Rhode Island, New Hampshire, Vermont, and Maine are smaller state markets. Their aging populations, however, sustain strong utilization of routine chemistry, cancer screening, diabetes testing, and chronic disease monitoring.

Growth in the Northeast is expected to trail the West because the region is more mature and population expansion is slower. Nevertheless, revenue per complex test is likely to remain high because of the concentration of academic medical centers, specialty medicine, clinical trials, precision oncology, and sophisticated payer-provider relationships.

Midwest

The Midwest represented approximately USD 4.60 billion in 2025 and is projected to reach approximately USD 8.11 billion by 2035, translating into a CAGR of roughly 5.8%.

The region includes Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin.

Illinois is the region’s largest state market, with approximately 12.72 million residents in 2025. Chicago’s healthcare ecosystem supports large academic hospitals, reference laboratories, community systems, outpatient networks, and specialty diagnostic demand.

Ohio, with approximately 11.90 million residents, is another major market. Cleveland, Columbus, and Cincinnati contain strong health systems and specialty care networks, supporting routine laboratory testing alongside oncology, cardiovascular, infectious-disease, and molecular diagnostics.

Michigan had approximately 10.13 million residents in 2025 and maintains a substantial hospital and laboratory market. Diabetes, cardiovascular disease, oncology, and other chronic conditions sustain recurring testing utilization.

Minnesota is strategically influential because of its medical technology industry, integrated health systems, major clinical institutions, and expertise in diagnostic development. Wisconsin, Indiana, and Missouri also provide stable demand across hospital and independent laboratory channels.

Iowa, Kansas, Nebraska, North Dakota, and South Dakota have smaller populations and greater rural exposure. Their commercial opportunity increasingly favors reliable regional laboratory logistics, point-of-care tests, and decentralized molecular platforms capable of reducing specimen transport delays.

The Midwest is expected to remain a durable rather than disruptive growth region. Manufacturers typically succeed through strong health-system contracting, dependable reagent supply, technical service, competitive cost per test, and diagnostic platforms capable of serving both large urban centers and regional hospital networks.

 

Key Market Players

The U.S. IVD test kits competitive landscape is moderately consolidated among major global diagnostics companies, but substantially more fragmented than many capital-equipment medical device markets. Competition varies by diagnostic discipline, with different leaders in central-laboratory immunoassay, molecular diagnostics, microbiology, rapid testing, women’s health, coagulation, consumer diagnostics, and specialty assays.

Some of the key companies participating in the U.S. IVD Test Kits industry include Roche Diagnostics; Abbott Laboratories; Danaher Corporation through Cepheid and Beckman Coulter; Siemens Healthineers; Becton, Dickinson and Company; bioMérieux; Bio-Rad Laboratories; QuidelOrtho; Hologic; QIAGEN; Thermo Fisher Scientific; DiaSorin; Revvity; Sysmex; Werfen; Grifols; Sekisui Diagnostics; Meridian Bioscience; Fujirebio Diagnostics; Trinity Biotech; OraSure Technologies; Seegene Technologies; Healgen Scientific; iHealth Labs; and Exact Sciences.

Roche, Abbott, Siemens Healthineers, Beckman Coulter, and QuidelOrtho benefit from extensive installed analyzer bases that create recurring demand for proprietary or platform-linked reagents. Once a health system standardizes on an analyzer ecosystem, switching costs can be meaningful because validation, middleware integration, staff training, quality controls, and purchasing contracts must all be reconsidered.

Danaher’s Cepheid business is particularly important in decentralized molecular diagnostics because cartridge-based workflows reduce traditional molecular laboratory complexity. Hologic maintains strong positions in women’s health and molecular testing, while BD combines microbiology, HPV, specimen collection, molecular systems, and extensive hospital relationships.

bioMérieux has a strong infectious-disease and microbiology presence, while QIAGEN competes across molecular sample preparation and diagnostic assays. Bio-Rad maintains important positions in quality controls, immunoassays, blood typing, and molecular technologies. DiaSorin, Revvity, Fujirebio, and Trinity Biotech provide additional competition in specialty immunodiagnostics.

OraSure, Healgen, iHealth, and other rapid-testing companies are increasingly important as consumer and near-patient testing expands. Their competitive advantage is based less on laboratory automation and more on manufacturing scale, retail distribution, simplicity, shelf life, and consumer usability.

Competitive advantage through 2035 will increasingly depend on platform economics rather than analytical sensitivity alone. Manufacturers will need to combine strong clinical evidence, efficient sample workflows, reimbursement support, scalable production, dependable U.S. supply chains, instrument connectivity, multiplexing, and clear economic benefits.

For health systems, the winning supplier is increasingly the company that lowers the total cost of generating an actionable diagnostic answer—not necessarily the company offering the lowest reagent price.

 

Recent Developments

The recent development environment shows that U.S. IVD innovation is moving rapidly toward decentralized molecular testing, self-collection, multi-analyte home testing, and cancer screening.

In June 2024, U.S. regulators permitted marketing of the first point-of-care hepatitis C RNA test. The system can detect HCV RNA from fingerstick blood and return results in approximately one hour in appropriately certified point-of-care settings. Commercially, this is important because it demonstrates the potential for molecular diagnostics to support same-visit diagnosis and linkage to treatment.

In May 2024, expanded approvals for Roche’s cobas HPV tests and BD’s Onclarity HPV assay allowed self-collected vaginal specimens obtained in healthcare settings to be used for high-risk HPV testing under the approved conditions. These developments marked an important step toward reducing barriers to cervical cancer screening.

In October 2024, the FDA approved Exact Sciences’ Cologuard Plus, a next-generation stool-based colorectal cancer screening test intended for average-risk adults aged 45 years and older. The approval reinforces the commercial viability of combining consumer specimen collection with sophisticated centralized molecular analysis.

Also in 2024, a combined COVID-19 and influenza A/B antigen test received De Novo authorization, establishing a traditional regulatory pathway for multi-analyte respiratory self-testing beyond emergency-use mechanisms. Additional combined respiratory products entered the market during 2025 and 2026, signaling a transition from COVID-specific home testing toward broader seasonal respiratory diagnostics.

In April 2026, a BD Onclarity self-collection product received U.S. clearance for home collection and transport of vaginal specimens by lay users for use with an approved HPV molecular assay. This is strategically important because home specimen collection could materially expand participation in cervical cancer screening among patients who face access, scheduling, geographic, or procedural barriers.

The regulatory environment has also changed materially. A federal district court vacated the FDA’s 2024 laboratory-developed-test final rule in March 2025, and in September 2025 the agency reverted the relevant regulatory language to its previous form. This reduced immediate regulatory disruption for laboratory-developed testing while preserving competitive uncertainty around the long-term relationship between commercial IVD manufacturers and high-complexity laboratory-developed assays.

Manufacturing requirements entered another important transition in February 2026, when the FDA’s Quality Management System Regulation became effective and incorporated ISO 13485:2016 into the U.S. medical-device quality-system framework. IVD companies must therefore place even greater emphasis on supplier qualification, risk management, design controls, process validation, complaint handling, and manufacturing documentation.

Reimbursement remains equally important. Legislation enacted in 2026 prevented a new phase-in reduction for applicable Medicare clinical laboratory payments during 2026. Updated private-payer data can affect rates from 2027 onward, with statutory limits on annual reductions through 2029. This creates temporary reimbursement stability but keeps laboratory economics and test pricing under continued scrutiny.

 

Conclusion

The U.S. IVD Test Kits Market Size & Share is positioned to expand from approximately USD 26.65 billion in 2025 to USD 53.41 billion by 2035, representing a 7.20% CAGR during 2026–2035.

The historical decline from pandemic-era revenue should not be interpreted as structural weakness. COVID-19 created an exceptional diagnostic testing cycle in 2021 and 2022. By 2025, the market had largely returned to a normalized base from which growth is increasingly supported by durable clinical demand rather than emergency testing.

The underlying market opportunity is exceptionally resilient. Approximately 14 billion laboratory tests are performed every year across more than 266,000 CLIA-certified U.S. laboratories. Diabetes affects tens of millions of Americans, cancer incidence exceeds two million cases annually, respiratory viruses create tens of millions of illnesses in severe seasons, and sexually transmitted infections continue to generate millions of reported cases. These disease burdens ensure continuing demand for diagnostic consumables.

The composition of that demand, however, will change substantially.

Routine chemistry, immunoassay, hematology, and conventional test strips will continue to produce high-volume recurring revenue. Faster growth will concentrate in multiplex molecular panels, oncology diagnostics, companion assays, high-value infectious-disease testing, HPV and women’s health products, consumer respiratory testing, stool-based cancer screening, and decentralized molecular cartridges.

The strongest commercial theme through 2035 will be the migration of diagnostics toward the patient. Central laboratories will remain essential for high-throughput and complex testing, but an increasing proportion of testing will be performed or initiated in emergency departments, urgent-care clinics, physician practices, pharmacies, community programs, and homes.

Regional opportunity will remain concentrated in the South because of population scale, chronic disease burden, infectious-disease requirements, and rapid growth in states such as Texas, Florida, Georgia, and North Carolina. The West is expected to achieve the fastest growth due to California’s diagnostics ecosystem, precision-medicine adoption, population expansion in Arizona and Nevada, and strong consumer acceptance of technology-enabled healthcare. The Northeast will remain critical for advanced molecular, oncology, and specialty diagnostics, while the Midwest will provide stable recurring demand and attractive decentralized-testing opportunities outside major metropolitan centers.

For manufacturers, investors, distributors, laboratories, and healthcare strategists, the central issue is therefore not simply the number of diagnostic tests performed. The more commercially important questions are which tests will migrate toward molecular and multiplex formats, which applications can support premium reimbursement, which specimen types can move to self-collection, how rapidly testing will decentralize, and which manufacturers can create a defensible recurring-reagent ecosystem around those changes.

Companies that combine analytical performance with workflow simplicity, payer alignment, manufacturing resilience, scalable distribution, multi-analyte capabilities, strong clinical evidence, and a lower total cost per actionable result are positioned to capture disproportionate value from the next decade of the U.S. IVD test kits industry.

 

TABLE OF CONTENT

1. U.S. IVD Test Kits Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Analytical Frameworks & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. IVD Test Kit and Reagent Manufacturers
1.6.2. Raw Material, Antibody, Enzyme, Primer and Component Suppliers
1.6.3. Diagnostic Platform and Analyzer Manufacturers
1.6.4. Hospital and Health System Laboratories
1.6.5. Independent and Reference Laboratories
1.6.6. Physician Office, Urgent Care and Point-of-Care Testing Providers
1.6.7. Retail Pharmacy, Home Testing and Consumer Diagnostic Channels
1.6.8. Group Purchasing Organizations and Laboratory Distributors
1.6.9. Payers, Regulators and Clinical Decision-Makers

What this section provides: This section defines the U.S. IVD test kits market boundary, inclusion and exclusion criteria, research methodology, assumptions, and stakeholder ecosystem so clients understand how recurring diagnostic kit revenue is measured, validated, and differentiated from instruments, software-only products, and laboratory services.

2. U.S. IVD Test Kits Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. COVID-Era Demand Normalization Analysis
2.8. High-Growth Opportunity Areas
2.9. Recurring Test Consumption and Installed-Base Economics

What this section provides: This section gives decision-makers a concise view of market size, historical normalization, 2025 positioning, forecast growth, recurring reagent economics, competitive intensity, and the diagnostic applications expected to create the strongest commercial opportunities through 2035.

3. U.S. IVD Test Kits Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. High Volume of Laboratory Testing Across the U.S.
3.1.2. Rising Chronic Disease and Aging Population Burden
3.1.3. Expansion of Molecular and Multiplex Diagnostics
3.1.4. Growth in Cancer Screening and Precision Oncology
3.1.5. Persistent Infectious Disease Testing Requirements
3.1.6. Expansion of Point-of-Care and Decentralized Testing
3.1.7. Increasing Consumer Acceptance of Self-Testing and Home Collection
3.1.8. Growth in Preventive Screening and Early Disease Detection
3.2. Restraints and Their Impact Analysis
3.2.1. Reimbursement and Clinical Laboratory Fee Pressure
3.2.2. Pricing Pressure in High-Volume Routine Testing
3.2.3. Complex FDA Regulatory and Quality Requirements
3.2.4. Laboratory Staffing and Skilled Workforce Constraints
3.2.5. Assay Validation and Laboratory Workflow Switching Costs
3.2.6. Commoditization of Mature Rapid Test Categories
3.3. Opportunities and Their Impact Analysis
3.3.1. Multiplex Molecular Diagnostic Panels
3.3.2. Oncology and Companion Diagnostic Test Kits
3.3.3. Home Collection and Self-Testing Platforms
3.3.4. Decentralized Molecular Testing
3.3.5. Women’s Health and HPV Self-Collection
3.3.6. Respiratory Combination Test Kits
3.3.7. STI and Sexual Health Testing
3.3.8. Antimicrobial Resistance Diagnostics
3.3.9. Digital PCR and High-Sensitivity Molecular Assays
3.4. Challenges and Their Impact Analysis
3.4.1. Reagent Supply Chain Vulnerability
3.4.2. Lot-to-Lot Consistency and Quality Control
3.4.3. Maintaining Clinical Differentiation in Crowded Assay Categories
3.4.4. Integration with Existing Laboratory Platforms
3.4.5. Patient Follow-Up After At-Home Testing
3.4.6. Seasonal Demand and Inventory Planning
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Clinical Laboratory Workflow Economics Analysis
3.6.1. Cost per Reportable Result
3.6.2. Hands-On Time and Laboratory Labor Requirements
3.6.3. Assay Throughput and Turnaround Time
3.6.4. Repeat Testing and Invalid Result Economics
3.6.5. Multiplexing and Revenue per Testing Episode
3.7. Laboratory Procurement Behavior Analysis
3.7.1. Reagent Rental and Installed-Base Models
3.7.2. Integrated Health System Standardization
3.7.3. Reference Laboratory Volume Contracting
3.7.4. GPO and Distributor Influence
3.7.5. Point-of-Care Procurement Dynamics

What this section provides: This section explains the clinical, demographic, reimbursement, technology, laboratory economics, and procurement forces shaping U.S. IVD test-kit demand, allowing clients to assess growth catalysts alongside adoption, pricing, regulatory, and execution risks.

4. U.S. IVD Test Kits Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry
4.3. Pricing Trend Analysis by Region, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.4.1. Biological Raw Materials
4.4.2. Antibodies, Antigens, Enzymes and Oligonucleotides
4.4.3. Membranes, Plastics and Cartridge Components
4.4.4. Assay Development and Manufacturing
4.4.5. Packaging, Distribution and Cold-Chain Requirements
4.4.6. Laboratory and Consumer Delivery Channels
4.5. Impact of Digitalization and Connected Diagnostics
4.6. Application & Innovation Landscape
4.7. FDA IVD Regulatory Framework Analysis
4.7.1. 510(k) Premarket Notification
4.7.2. De Novo Classification
4.7.3. Premarket Approval
4.7.4. Emergency Use Authorization Legacy and Transition
4.7.5. CLIA Waiver Considerations
4.7.6. Laboratory-Developed Test Regulatory Environment
4.7.7. Quality Management System Regulation
4.8. CMS Reimbursement and Coverage Landscape
4.8.1. Clinical Laboratory Fee Schedule
4.8.2. PAMA-Related Laboratory Payment Dynamics
4.8.3. Molecular Diagnostic Reimbursement
4.8.4. Preventive Screening Coverage
4.8.5. Commercial Payer Considerations
4.9. CLIA Laboratory Regulatory Environment
4.10. Import/Export Restrictions & Tariff Impact
4.11. Government Initiatives and Public Health Screening Programs
4.12. Impact of Escalating Geopolitical Tensions
4.13. Laboratory Value Analysis and Assay Adoption Decision Framework
4.14. Reagent Supply Security and Domestic Manufacturing Analysis

What this section provides: This section gives clients a complete view of the U.S. IVD operating environment, including FDA regulation, CLIA requirements, CMS reimbursement, pricing, supply-chain exposure, laboratory economics, diagnostic digitalization, and assay adoption criteria.

5. U.S. IVD Test Kits Market – By Product Format

5.1. Overview
5.1.1. Segment Share Analysis, By Product Format, 2025 & 2035 (%)
5.1.2. Reagent and Assay Kits
5.1.2.1. Clinical Chemistry Reagent Kits
5.1.2.2. Immunoassay Reagent Kits
5.1.2.3. Hematology Reagent Kits
5.1.2.4. Coagulation Assay Kits
5.1.2.5. Microbiology Reagent Kits
5.1.2.6. Calibrators and Controls
5.1.3. Molecular Diagnostic Cartridges and Closed-System Kits
5.1.3.1. Single-Target Molecular Kits
5.1.3.2. Multiplex Molecular Panels
5.1.3.3. Closed-Cartridge PCR Kits
5.1.3.4. Isothermal Amplification Kits
5.1.4. Rapid Cassette and Lateral-Flow Test Kits
5.1.4.1. Infectious Disease Rapid Tests
5.1.4.2. Pregnancy and Fertility Tests
5.1.4.3. Cardiac and Metabolic Rapid Tests
5.1.4.4. Drugs-of-Abuse Rapid Tests
5.1.5. Test Strips and Dipstick-Based Kits
5.1.5.1. Glucose Test Strips
5.1.5.2. Urinalysis Strips
5.1.5.3. Ketone Test Strips
5.1.5.4. Fecal Occult Blood Tests
5.1.5.5. Other Diagnostic Strips
5.1.6. Self-Test and Integrated Home Testing Kits
5.1.6.1. Home Respiratory Test Kits
5.1.6.2. Reproductive Health Test Kits
5.1.6.3. Home Sample Collection Kits
5.1.6.4. Sexual Health Test Kits
5.1.6.5. Preventive Screening Kits

What this section provides: This section identifies the product formats generating the largest recurring revenues and determines which assay, cartridge, rapid-test, strip-based, and home-testing formats are expected to gain share through 2035.

6. U.S. IVD Test Kits Market – By Technology

6.1. Overview
6.1.1. Segment Share Analysis, By Technology, 2025 & 2035 (%)
6.1.2. Immunoassay
6.1.2.1. Chemiluminescence Immunoassay
6.1.2.2. Enzyme-Linked Immunosorbent Assay
6.1.2.3. Fluorescence Immunoassay
6.1.2.4. Lateral-Flow Immunoassay
6.1.2.5. Other Immunoassay Technologies
6.1.3. Molecular Diagnostics
6.1.3.1. Polymerase Chain Reaction
6.1.3.2. Real-Time PCR and RT-PCR
6.1.3.3. Digital PCR
6.1.3.4. Isothermal Nucleic Acid Amplification
6.1.3.5. Hybridization-Based Assays
6.1.3.6. Targeted Sequencing and Genotyping Assays
6.1.4. Clinical Chemistry
6.1.4.1. Enzymatic Assays
6.1.4.2. Colorimetric Assays
6.1.4.3. Electrolyte and Metabolite Assays
6.1.4.4. Specialty Chemistry Assays
6.1.5. Hematology and Coagulation
6.1.5.1. Hematology Reagents
6.1.5.2. Coagulation Assays
6.1.5.3. Hemostasis and Thrombosis Testing
6.1.5.4. Specialty Hematology Assays
6.1.6. Microbiology, Urinalysis and Other Technologies
6.1.6.1. Culture and Identification
6.1.6.2. Antimicrobial Susceptibility Testing
6.1.6.3. Urinalysis
6.1.6.4. Electrophoresis
6.1.6.5. Other IVD Technologies

What this section provides: This section evaluates the diagnostic technologies shaping future test-kit demand and helps clients compare mature high-volume platforms with faster-growing molecular, multiplex, and high-sensitivity assay technologies.

7. U.S. IVD Test Kits Market – By Application

7.1. Overview
7.1.1. Segment Share Analysis, By Application, 2025 & 2035 (%)
7.1.2. Infectious Diseases
7.1.2.1. Respiratory Infections
7.1.2.2. Sexually Transmitted Infections
7.1.2.3. HIV
7.1.2.4. Hepatitis
7.1.2.5. Gastrointestinal Infections
7.1.2.6. Urinary Tract Infections
7.1.2.7. Bloodstream Infections
7.1.2.8. Antimicrobial Resistance Testing
7.1.2.9. Other Infectious Diseases
7.1.3. Oncology
7.1.3.1. Cancer Screening
7.1.3.2. Tumor Biomarker Testing
7.1.3.3. Molecular Tumor Profiling
7.1.3.4. Companion Diagnostics
7.1.3.5. Hereditary Cancer Testing
7.1.3.6. Recurrence and Disease Monitoring
7.1.4. Diabetes and Cardiometabolic Disorders
7.1.4.1. Diabetes Testing
7.1.4.2. Lipid Testing
7.1.4.3. Cardiac Biomarkers
7.1.4.4. Renal Function Testing
7.1.4.5. Metabolic Disease Testing
7.1.5. Women’s Health, Reproductive Health and Sexual Health
7.1.5.1. Pregnancy Testing
7.1.5.2. Fertility and Ovulation Testing
7.1.5.3. HPV and Cervical Cancer Screening
7.1.5.4. Prenatal Testing
7.1.5.5. Vaginitis Testing
7.1.5.6. STI Screening
7.1.6. Endocrine, Autoimmune, Gastrointestinal, Renal and Other Applications
7.1.6.1. Thyroid and Endocrine Disorders
7.1.6.2. Autoimmune Disorders
7.1.6.3. Gastrointestinal Disorders
7.1.6.4. Kidney Disease
7.1.6.5. Allergy Testing
7.1.6.6. Therapeutic Drug Monitoring
7.1.6.7. Toxicology
7.1.6.8. Transplant Diagnostics
7.1.6.9. Other Clinical Applications

What this section provides: This section explains demand by clinical application and identifies where disease prevalence, screening expansion, molecular testing, reimbursement, and clinical utility are expected to generate the strongest test-kit revenue opportunities.

8. U.S. IVD Test Kits Market – By Sample Type

8.1. Overview
8.1.1. Segment Share Analysis, By Sample Type, 2025 & 2035 (%)
8.1.2. Blood, Serum and Plasma
8.1.2.1. Venous Whole Blood
8.1.2.2. Capillary and Fingerstick Blood
8.1.2.3. Serum
8.1.2.4. Plasma
8.1.3. Respiratory Swabs and Saliva
8.1.3.1. Nasal Swabs
8.1.3.2. Nasopharyngeal Swabs
8.1.3.3. Oropharyngeal Swabs
8.1.3.4. Saliva
8.1.4. Urine
8.1.4.1. Routine Urinalysis
8.1.4.2. Pregnancy Testing
8.1.4.3. STI Testing
8.1.4.4. Drug and Toxicology Testing
8.1.5. Stool
8.1.5.1. Colorectal Cancer Screening
8.1.5.2. Gastrointestinal Pathogen Testing
8.1.5.3. Fecal Occult Blood Testing
8.1.5.4. Inflammatory and Other Biomarker Testing
8.1.6. Tissue, Cytology and Other Specimens
8.1.6.1. Tissue Specimens
8.1.6.2. Cervical and Vaginal Specimens
8.1.6.3. Cerebrospinal Fluid
8.1.6.4. Semen
8.1.6.5. Other Specialty Specimens

What this section provides: This section evaluates how specimen type influences testing workflow, decentralization, self-collection potential, assay complexity, clinical use, and future commercial opportunity.

9. U.S. IVD Test Kits Market – By End User

9.1. Overview
9.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
9.1.2. Hospital and Health System Laboratories
9.1.2.1. Core Laboratories
9.1.2.2. Emergency and STAT Laboratories
9.1.2.3. Specialty Hospital Laboratories
9.1.2.4. Integrated Health System Laboratory Networks
9.1.3. Independent and Reference Laboratories
9.1.3.1. National Reference Laboratories
9.1.3.2. Regional Independent Laboratories
9.1.3.3. Specialty Molecular and Genetic Laboratories
9.1.4. Physician Offices, Urgent Care Centers and Retail Clinics
9.1.4.1. Physician Office Laboratories
9.1.4.2. Urgent Care Centers
9.1.4.3. Retail Clinics and Pharmacies
9.1.4.4. Community Health Centers
9.1.5. Public Health Laboratories, Blood Banks and Community Testing Programs
9.1.5.1. Federal and State Public Health Laboratories
9.1.5.2. Blood Banks and Blood Centers
9.1.5.3. Community Screening Programs
9.1.5.4. Correctional and Institutional Testing Programs
9.1.6. Home and Consumer Testing
9.1.6.1. Direct-to-Consumer Self-Testing
9.1.6.2. At-Home Sample Collection
9.1.6.3. Retail-Purchased Diagnostic Kits
9.1.6.4. Digitally Connected Home Testing

What this section provides: This section identifies the care settings and customer groups expected to drive recurring test consumption and assesses how hospital laboratories, reference laboratories, decentralized care sites, and consumers differ in purchasing criteria and adoption behavior.

10. U.S. IVD Test Kits Market – By Geography

10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional Diagnostic Testing Volume and CLIA Laboratory Infrastructure Analysis
10.1.4. Regional Disease Burden and Testing Demand Analysis
10.1.5. Regional Reimbursement and Laboratory Procurement Dynamics
10.1.6. Regional Molecular, Point-of-Care and Home Testing Adoption Analysis
10.2. West Region
10.2.1. Regional Overview & Trends
10.2.2. West Region IVD Test Kit Key Manufacturers, Laboratories and Distribution Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.8. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.9. California
10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.2.9.3. California Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.9.4. California Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.9.5. California Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.9.6. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.10. Washington
10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.2.10.3. Washington Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.10.4. Washington Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.10.5. Washington Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.10.6. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.11. Arizona
10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.2.11.3. Arizona Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.11.4. Arizona Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.11.5. Arizona Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.11.6. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.12. Colorado
10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.2.12.3. Colorado Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.12.4. Colorado Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.12.5. Colorado Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.12.6. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.13. Oregon
10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.2.13.3. Oregon Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.13.4. Oregon Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.13.5. Oregon Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.13.6. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.14. Utah
10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.2.14.3. Utah Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.14.4. Utah Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.14.5. Utah Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.14.6. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.15. Nevada
10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.2.15.3. Nevada Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.15.4. Nevada Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.15.5. Nevada Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.15.6. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.16. New Mexico
10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.2.16.3. New Mexico Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.16.4. New Mexico Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.16.5. New Mexico Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.16.6. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.17. Idaho
10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.2.17.3. Idaho Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.17.4. Idaho Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.17.5. Idaho Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.17.6. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.18. Montana
10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.2.18.3. Montana Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.18.4. Montana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.18.5. Montana Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.18.6. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.19. Wyoming
10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.2.19.3. Wyoming Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.19.4. Wyoming Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.19.5. Wyoming Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.19.6. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.20. Alaska
10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.2.20.3. Alaska Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.20.4. Alaska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.20.5. Alaska Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.20.6. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.21. Hawaii
10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.2.21.3. Hawaii Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.21.4. Hawaii Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.21.5. Hawaii Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.21.6. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3. Northeast Region
10.3.1. Regional Overview & Trends
10.3.2. Northeast Region IVD Test Kit Key Manufacturers, Laboratories and Distribution Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.3.4. Northeast Region Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.3.5. Northeast Region Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.6. Northeast Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.7. Northeast Region Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.3.8. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.9. New York
10.3.9.1. Overview
10.3.9.2. New York Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.3.9.3. New York Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.9.4. New York Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.9.5. New York Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.3.9.6. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.10. Massachusetts
10.3.10.1. Overview
10.3.10.2. Massachusetts Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.3.10.3. Massachusetts Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.10.4. Massachusetts Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.10.5. Massachusetts Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.3.10.6. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.11. New Jersey
10.3.11.1. Overview
10.3.11.2. New Jersey Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.3.11.3. New Jersey Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.11.4. New Jersey Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.11.5. New Jersey Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.3.11.6. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.12. Pennsylvania
10.3.12.1. Overview
10.3.12.2. Pennsylvania Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.3.12.3. Pennsylvania Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.12.4. Pennsylvania Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.12.5. Pennsylvania Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.3.12.6. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.13. Connecticut
10.3.13.1. Overview
10.3.13.2. Connecticut Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.3.13.3. Connecticut Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.13.4. Connecticut Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.13.5. Connecticut Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.3.13.6. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.14. Maine
10.3.14.1. Overview
10.3.14.2. Maine Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.3.14.3. Maine Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.14.4. Maine Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.14.5. Maine Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.3.14.6. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.15. Vermont
10.3.15.1. Overview
10.3.15.2. Vermont Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.3.15.3. Vermont Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.15.4. Vermont Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.15.5. Vermont Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.3.15.6. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.16. New Hampshire
10.3.16.1. Overview
10.3.16.2. New Hampshire Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.3.16.3. New Hampshire Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.16.4. New Hampshire Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.16.5. New Hampshire Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.3.16.6. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.17. Rhode Island
10.3.17.1. Overview
10.3.17.2. Rhode Island Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.3.17.3. Rhode Island Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.17.4. Rhode Island Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.17.5. Rhode Island Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.3.17.6. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.18. Delaware
10.3.18.1. Overview
10.3.18.2. Delaware Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.3.18.3. Delaware Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.18.4. Delaware Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.18.5. Delaware Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.3.18.6. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4. South Region
10.4.1. Regional Overview & Trends
10.4.2. South Region IVD Test Kit Key Manufacturers, Laboratories and Distribution Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.4.4. South Region Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.4.5. South Region Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.6. South Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.7. South Region Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.8. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.9. Texas
10.4.9.1. Overview
10.4.9.2. Texas Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.4.9.3. Texas Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.9.4. Texas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.9.5. Texas Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.9.6. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.10. Florida
10.4.10.1. Overview
10.4.10.2. Florida Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.4.10.3. Florida Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.10.4. Florida Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.10.5. Florida Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.10.6. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.11. Georgia
10.4.11.1. Overview
10.4.11.2. Georgia Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.4.11.3. Georgia Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.11.4. Georgia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.11.5. Georgia Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.11.6. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.12. North Carolina
10.4.12.1. Overview
10.4.12.2. North Carolina Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.4.12.3. North Carolina Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.12.4. North Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.12.5. North Carolina Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.12.6. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.13. Tennessee
10.4.13.1. Overview
10.4.13.2. Tennessee Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.4.13.3. Tennessee Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.13.4. Tennessee Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.13.5. Tennessee Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.13.6. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.14. South Carolina
10.4.14.1. Overview
10.4.14.2. South Carolina Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.4.14.3. South Carolina Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.14.4. South Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.14.5. South Carolina Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.14.6. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.15. Alabama
10.4.15.1. Overview
10.4.15.2. Alabama Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.4.15.3. Alabama Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.15.4. Alabama Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.15.5. Alabama Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.15.6. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.16. Mississippi
10.4.16.1. Overview
10.4.16.2. Mississippi Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.4.16.3. Mississippi Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.16.4. Mississippi Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.16.5. Mississippi Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.16.6. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.17. Louisiana
10.4.17.1. Overview
10.4.17.2. Louisiana Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.4.17.3. Louisiana Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.17.4. Louisiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.17.5. Louisiana Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.17.6. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.18. Arkansas
10.4.18.1. Overview
10.4.18.2. Arkansas Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.4.18.3. Arkansas Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.18.4. Arkansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.18.5. Arkansas Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.18.6. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.19. Kentucky
10.4.19.1. Overview
10.4.19.2. Kentucky Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.4.19.3. Kentucky Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.19.4. Kentucky Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.19.5. Kentucky Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.19.6. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.20. Oklahoma
10.4.20.1. Overview
10.4.20.2. Oklahoma Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.4.20.3. Oklahoma Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.20.4. Oklahoma Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.20.5. Oklahoma Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.20.6. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.21. Virginia
10.4.21.1. Overview
10.4.21.2. Virginia Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.4.21.3. Virginia Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.21.4. Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.21.5. Virginia Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.21.6. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.22. Maryland
10.4.22.1. Overview
10.4.22.2. Maryland Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.4.22.3. Maryland Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.22.4. Maryland Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.22.5. Maryland Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.22.6. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.23. West Virginia
10.4.23.1. Overview
10.4.23.2. West Virginia Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.4.23.3. West Virginia Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.23.4. West Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.23.5. West Virginia Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.23.6. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5. Midwest Region
10.5.1. Regional Overview & Trends
10.5.2. Midwest Region IVD Test Kit Key Manufacturers, Laboratories and Distribution Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.5.4. Midwest Region Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.5.5. Midwest Region Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.6. Midwest Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.7. Midwest Region Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.8. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.9. Illinois
10.5.9.1. Overview
10.5.9.2. Illinois Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.5.9.3. Illinois Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.9.4. Illinois Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.9.5. Illinois Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.9.6. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.10. Ohio
10.5.10.1. Overview
10.5.10.2. Ohio Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.5.10.3. Ohio Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.10.4. Ohio Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.10.5. Ohio Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.10.6. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.11. Michigan
10.5.11.1. Overview
10.5.11.2. Michigan Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.5.11.3. Michigan Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.11.4. Michigan Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.11.5. Michigan Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.11.6. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.12. Minnesota
10.5.12.1. Overview
10.5.12.2. Minnesota Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.5.12.3. Minnesota Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.12.4. Minnesota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.12.5. Minnesota Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.12.6. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.13. Indiana
10.5.13.1. Overview
10.5.13.2. Indiana Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.5.13.3. Indiana Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.13.4. Indiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.13.5. Indiana Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.13.6. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.14. Wisconsin
10.5.14.1. Overview
10.5.14.2. Wisconsin Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.5.14.3. Wisconsin Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.14.4. Wisconsin Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.14.5. Wisconsin Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.14.6. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.15. Missouri
10.5.15.1. Overview
10.5.15.2. Missouri Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.5.15.3. Missouri Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.15.4. Missouri Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.15.5. Missouri Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.15.6. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.16. Iowa
10.5.16.1. Overview
10.5.16.2. Iowa Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.5.16.3. Iowa Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.16.4. Iowa Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.16.5. Iowa Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.16.6. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.17. Kansas
10.5.17.1. Overview
10.5.17.2. Kansas Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.5.17.3. Kansas Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.17.4. Kansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.17.5. Kansas Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.17.6. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.18. Nebraska
10.5.18.1. Overview
10.5.18.2. Nebraska Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.5.18.3. Nebraska Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.18.4. Nebraska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.18.5. Nebraska Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.18.6. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.19. North Dakota
10.5.19.1. Overview
10.5.19.2. North Dakota Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.5.19.3. North Dakota Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.19.4. North Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.19.5. North Dakota Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.19.6. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.20. South Dakota
10.5.20.1. Overview
10.5.20.2. South Dakota Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.5.20.3. South Dakota Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.20.4. South Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.20.5. South Dakota Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.20.6. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

What this section provides: This section delivers detailed regional and state-level analysis across all 50 states, helping clients identify priority diagnostic markets, CLIA laboratory hubs, molecular-testing hotspots, disease-driven demand centers, decentralized-testing opportunities, and state-level commercial expansion priorities.

11. U.S. IVD Test Kits Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.2. Competitive Concentration Analysis
11.3. Company Positioning Matrix
11.3.1. Leaders
11.3.2. Challengers
11.3.3. Innovators
11.3.4. Emerging Players
11.4. Competitive Benchmarking
11.4.1. Assay Menu Breadth
11.4.2. Molecular Diagnostic Capabilities
11.4.3. Installed Instrument Base
11.4.4. Point-of-Care Presence
11.4.5. Home Testing Exposure
11.4.6. U.S. Regulatory Pipeline
11.4.7. Laboratory Contracting Strength
11.5. Company Profiles
11.5.1. Roche Diagnostics
11.5.2. Abbott Laboratories
11.5.3. Danaher Corporation
11.5.4. Siemens Healthineers
11.5.5. Becton, Dickinson and Company
11.5.6. bioMérieux
11.5.7. Bio-Rad Laboratories
11.5.8. QuidelOrtho Corporation
11.5.9. Hologic, Inc.
11.5.10. QIAGEN
11.5.11. Thermo Fisher Scientific
11.5.12. DiaSorin
11.5.13. Revvity
11.5.14. Sysmex Corporation
11.5.15. Werfen
11.5.16. Grifols
11.5.17. Sekisui Diagnostics
11.5.18. Meridian Bioscience
11.5.19. Fujirebio Diagnostics
11.5.20. Trinity Biotech
11.5.21. OraSure Technologies
11.5.22. Seegene Technologies
11.5.23. Healgen Scientific
11.5.24. iHealth Labs
11.5.25. Exact Sciences Corporation

Note: Each company profile will include company overview, U.S. IVD test-kit portfolio, key assay technologies, product positioning, U.S. market strategy, laboratory and distribution presence, financial positioning, FDA regulatory developments, innovation pipeline, partnerships, acquisitions, product launches, and recent strategic developments.

What this section provides: This section gives clients market-share visibility, competitor benchmarking, assay portfolio comparisons, molecular and point-of-care positioning, regulatory intelligence, and strategic insights into 25 important participants in the U.S. IVD test kits competitive ecosystem.

12. U.S. IVD Test Kits Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario
12.2. Disruptive Technologies Impact
12.2.1. Multiplex Molecular Diagnostic Panels
12.2.2. Digital PCR and Ultra-Sensitive Molecular Testing
12.2.3. Cartridge-Based Sample-to-Answer Diagnostics
12.2.4. Home Self-Testing and Self-Collection
12.2.5. AI-Assisted Diagnostic Interpretation
12.2.6. Liquid Biopsy and Molecular Oncology
12.2.7. Syndromic Infectious Disease Testing
12.2.8. Microfluidic and Miniaturized Diagnostic Platforms
12.3. Emerging Business Trends
12.3.1. Shift from Single-Analyte to Multi-Analyte Testing
12.3.2. Consumerization of Diagnostics
12.3.3. Laboratory Consolidation
12.3.4. Reagent Rental and Subscription-Based Commercial Models
12.3.5. Increasing Domestic Supply-Chain Resilience
12.3.6. Expansion of Decentralized Molecular Testing
12.4. Business Opportunities for Startups and Existing Players
12.5. Investment Prioritization Matrix
12.6. High-Growth Application Opportunity Matrix
12.7. Future Laboratory Workflow Transformation

What this section provides: This section prepares clients for shifts in assay technology, testing location, laboratory structure, reimbursement, consumer behavior, and investment priorities that could reshape the U.S. IVD test kits market through 2035.

13. U.S. IVD Test Kits Market: Strategic Recommendations

13.1. Recommendations for IVD Test Kit Manufacturers
13.2. Recommendations for Hospital and Health System Laboratories
13.3. Recommendations for Independent and Reference Laboratories
13.4. Recommendations for Investors and Private Equity Firms
13.5. Recommendations for Distributors and Channel Partners
13.6. Recommendations for New Entrants and Diagnostic Startups
13.7. Go-to-Market Strategy Considerations
13.8. Product Positioning and Assay Portfolio Expansion Guidance
13.9. Molecular Diagnostics Commercialization Strategy
13.10. Point-of-Care and CLIA-Waived Market Entry Strategy
13.11. Home Testing and Consumer Diagnostics Strategy
13.12. Reimbursement and Evidence Generation Strategy
13.13. Laboratory Contracting and Installed-Base Strategy

What this section provides: This section translates market intelligence into actionable recommendations for assay portfolio development, laboratory contracting, point-of-care expansion, reimbursement strategy, consumer diagnostics, investment decisions, and long-term competitive differentiation.

14. U.S. IVD Test Kits Market: Disclaimer

14.1. Scope Limitation
14.2. Data Use Limitation
14.3. Forecasting Limitation
14.4. Legal Disclaimer
14.5. Third-Party Data Disclaimer
14.6. Regulatory and Reimbursement Data Limitation

What this section provides: This section clarifies the report’s market-definition boundaries, data-use conditions, forecasting limitations, regulatory assumptions, reimbursement considerations, and legal limitations.

 

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. IVD Test Kits Market: Market Definition and Scope
TABLE 3: U.S. IVD Test Kits Market: Research Methodology Framework
TABLE 4: U.S. IVD Test Kits Market: Key Assumptions
TABLE 5: U.S. IVD Test Kits Market: Market Ecosystem Overview
TABLE 6: U.S. IVD Test Kits Market: Stakeholder Analysis
TABLE 7: U.S. IVD Test Kits Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. IVD Test Kits Market: Analyst Viewpoint Summary
TABLE 9: U.S. IVD Test Kits Market: Market Attractiveness Index
TABLE 10: U.S. IVD Test Kits Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. IVD Test Kits Market: Base Year Market Positioning, 2025
TABLE 12: U.S. IVD Test Kits Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 13: U.S. IVD Test Kits Market: COVID-Era Demand Normalization and High-Growth Opportunity Analysis
TABLE 14: U.S. IVD Test Kits Market: Drivers; Impact Analysis
TABLE 15: U.S. IVD Test Kits Market: Restraints; Impact Analysis
TABLE 16: U.S. IVD Test Kits Market: Opportunities; Impact Analysis
TABLE 17: U.S. IVD Test Kits Market: Challenges; Impact Analysis
TABLE 18: U.S. IVD Test Kits Market: Patent & Innovation Analysis, 2021–2025
TABLE 19: U.S. IVD Test Kits Market: Clinical Laboratory Workflow Economics Matrix
TABLE 20: U.S. IVD Test Kits Market: Cost per Reportable Result Analysis
TABLE 21: U.S. IVD Test Kits Market: Assay Throughput and Turnaround Time Benchmarking
TABLE 22: U.S. IVD Test Kits Market: Laboratory Procurement Behavior Matrix
TABLE 23: U.S. IVD Test Kits Market: Reagent Rental and Installed-Base Economics
TABLE 24: U.S. IVD Test Kits Market: Decentralized Testing Opportunity Matrix
TABLE 25: U.S. IVD Test Kits Market: Home Testing and Self-Collection Opportunity Analysis
TABLE 26: U.S. IVD Test Kits Market: PESTEL Analysis
TABLE 27: U.S. IVD Test Kits Market: Porter’s Five Forces Analysis
TABLE 28: U.S. IVD Test Kits Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 29: U.S. IVD Test Kits Market: Value Chain Analysis
TABLE 30: U.S. IVD Test Kits Market: Supply Chain Analysis
TABLE 31: U.S. IVD Test Kits Market: Critical Raw Material and Reagent Supply Analysis
TABLE 32: U.S. IVD Test Kits Market: Digitalization and Connected Diagnostics Impact
TABLE 33: U.S. IVD Test Kits Market: Application & Innovation Landscape
TABLE 34: U.S. IVD Test Kits Market: FDA Regulatory Framework Analysis
TABLE 35: U.S. IVD Test Kits Market: 510(k), De Novo and PMA Pathway Comparison
TABLE 36: U.S. IVD Test Kits Market: CLIA and CLIA-Waived Testing Landscape
TABLE 37: U.S. IVD Test Kits Market: CMS Clinical Laboratory Reimbursement Landscape
TABLE 38: U.S. IVD Test Kits Market: Import/Export Restrictions & Tariff Impact
TABLE 39: U.S. IVD Test Kits Market: Government Initiatives and Public Health Programs
TABLE 40: U.S. IVD Test Kits Market: Laboratory Value Analysis and Assay Adoption Framework
TABLE 41: U.S. IVD Test Kits Market: Product Format Snapshot, 2025
TABLE 42: Segment Dashboard; Definition and Scope, by Product Format
TABLE 43: U.S. IVD Test Kits Market, by Product Format, 2021–2035 (US$ Billion)
TABLE 44: U.S. IVD Test Kits Market: Segment Share Analysis, by Product Format, 2025 & 2035 (%)
TABLE 45: U.S. IVD Test Kits Market: Reagent and Assay Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 46: U.S. IVD Test Kits Market: Molecular Diagnostic Cartridges and Closed-System Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 47: U.S. IVD Test Kits Market: Rapid Cassette and Lateral-Flow Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 48: U.S. IVD Test Kits Market: Test Strips and Dipstick-Based Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 49: U.S. IVD Test Kits Market: Self-Test and Integrated Home Testing Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 50: U.S. IVD Test Kits Market: Technology Snapshot, 2025
TABLE 51: Segment Dashboard; Definition and Scope, by Technology
TABLE 52: U.S. IVD Test Kits Market, by Technology, 2021–2035 (US$ Billion)
TABLE 53: U.S. IVD Test Kits Market: Segment Share Analysis, by Technology, 2025 & 2035 (%)
TABLE 54: U.S. IVD Test Kits Market: Immunoassay Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 55: U.S. IVD Test Kits Market: Molecular Diagnostics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 56: U.S. IVD Test Kits Market: Clinical Chemistry Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 57: U.S. IVD Test Kits Market: Hematology and Coagulation Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 58: U.S. IVD Test Kits Market: Microbiology, Urinalysis and Other Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 59: U.S. IVD Test Kits Market: Application Snapshot, 2025
TABLE 60: Segment Dashboard; Definition and Scope, by Application
TABLE 61: U.S. IVD Test Kits Market, by Application, 2021–2035 (US$ Billion)
TABLE 62: U.S. IVD Test Kits Market: Segment Share Analysis, by Application, 2025 & 2035 (%)
TABLE 63: U.S. IVD Test Kits Market: Infectious Diseases Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 64: U.S. IVD Test Kits Market: Oncology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 65: U.S. IVD Test Kits Market: Diabetes and Cardiometabolic Disorders Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 66: U.S. IVD Test Kits Market: Women’s Health, Reproductive Health and Sexual Health Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 67: U.S. IVD Test Kits Market: Endocrine, Autoimmune, Gastrointestinal, Renal and Other Applications Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 68: U.S. IVD Test Kits Market: Sample Type Snapshot, 2025
TABLE 69: Segment Dashboard; Definition and Scope, by Sample Type
TABLE 70: U.S. IVD Test Kits Market, by Sample Type, 2021–2035 (US$ Billion)
TABLE 71: U.S. IVD Test Kits Market: Segment Share Analysis, by Sample Type, 2025 & 2035 (%)
TABLE 72: U.S. IVD Test Kits Market: Blood, Serum and Plasma Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 73: U.S. IVD Test Kits Market: Respiratory Swabs and Saliva Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 74: U.S. IVD Test Kits Market: Urine Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 75: U.S. IVD Test Kits Market: Stool Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 76: U.S. IVD Test Kits Market: Tissue, Cytology and Other Specimens Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 77: U.S. IVD Test Kits Market: End User Snapshot, 2025
TABLE 78: Segment Dashboard; Definition and Scope, by End User
TABLE 79: U.S. IVD Test Kits Market, by End User, 2021–2035 (US$ Billion)
TABLE 80: U.S. IVD Test Kits Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 81: U.S. IVD Test Kits Market: Hospital and Health System Laboratories Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 82: U.S. IVD Test Kits Market: Independent and Reference Laboratories Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 83: U.S. IVD Test Kits Market: Physician Offices, Urgent Care Centers and Retail Clinics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 84: U.S. IVD Test Kits Market: Public Health Laboratories, Blood Banks and Community Testing Programs Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 85: U.S. IVD Test Kits Market: Home and Consumer Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 86: U.S. IVD Test Kits Market: Regional Snapshot, 2025
TABLE 87: Segment Dashboard; Definition and Scope, by Region
TABLE 88: U.S. IVD Test Kits Market, by Region, 2021–2035 (US$ Billion)
TABLE 89: U.S. IVD Test Kits Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 90: U.S. IVD Test Kits Market: Regional Diagnostic Testing Volume and CLIA Laboratory Infrastructure
TABLE 91: U.S. IVD Test Kits Market: Regional Disease Burden and Testing Demand Analysis
TABLE 92: West Region U.S. IVD Test Kits Market: Regional Overview and Trends
TABLE 93: West Region U.S. IVD Test Kits Market: Key Manufacturers, Laboratories and Distribution Ecosystem
TABLE 94: West Region U.S. IVD Test Kits Market, by State, 2021–2035 (US$ Billion)
TABLE 95: West Region U.S. IVD Test Kits Market, by Product Format, 2021–2035 (US$ Billion)
TABLE 96: West Region U.S. IVD Test Kits Market, by Technology, 2021–2035 (US$ Billion)
TABLE 97: West Region U.S. IVD Test Kits Market, by Application, 2021–2035 (US$ Billion)
TABLE 98: West Region U.S. IVD Test Kits Market, by Sample Type, 2021–2035 (US$ Billion)
TABLE 99: West Region U.S. IVD Test Kits Market, by End User, 2021–2035 (US$ Billion)
TABLE 100: California IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 101: Washington IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 102: Arizona IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 103: Colorado IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 104: Oregon IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 105: Utah IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 106: Nevada IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 107: New Mexico IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 108: Idaho IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 109: Montana IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 110: Wyoming IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 111: Alaska IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 112: Hawaii IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 113: Northeast Region U.S. IVD Test Kits Market: Regional Overview and Trends
TABLE 114: Northeast Region U.S. IVD Test Kits Market: Key Manufacturers, Laboratories and Distribution Ecosystem
TABLE 115: Northeast Region U.S. IVD Test Kits Market, by State, 2021–2035 (US$ Billion)
TABLE 116: Northeast Region U.S. IVD Test Kits Market, by Product Format, 2021–2035 (US$ Billion)
TABLE 117: Northeast Region U.S. IVD Test Kits Market, by Technology, 2021–2035 (US$ Billion)
TABLE 118: Northeast Region U.S. IVD Test Kits Market, by Application, 2021–2035 (US$ Billion)
TABLE 119: Northeast Region U.S. IVD Test Kits Market, by Sample Type, 2021–2035 (US$ Billion)
TABLE 120: Northeast Region U.S. IVD Test Kits Market, by End User, 2021–2035 (US$ Billion)
TABLE 121: New York IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 122: Massachusetts IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 123: New Jersey IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 124: Pennsylvania IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 125: Connecticut IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 126: Maine IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 127: Vermont IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 128: New Hampshire IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 129: Rhode Island IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 130: Delaware IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 131: South Region U.S. IVD Test Kits Market: Regional Overview and Trends
TABLE 132: South Region U.S. IVD Test Kits Market: Key Manufacturers, Laboratories and Distribution Ecosystem
TABLE 133: South Region U.S. IVD Test Kits Market, by State, 2021–2035 (US$ Billion)
TABLE 134: South Region U.S. IVD Test Kits Market, by Product Format, 2021–2035 (US$ Billion)
TABLE 135: South Region U.S. IVD Test Kits Market, by Technology, 2021–2035 (US$ Billion)
TABLE 136: South Region U.S. IVD Test Kits Market, by Application, 2021–2035 (US$ Billion)
TABLE 137: South Region U.S. IVD Test Kits Market, by Sample Type, 2021–2035 (US$ Billion)
TABLE 138: South Region U.S. IVD Test Kits Market, by End User, 2021–2035 (US$ Billion)
TABLE 139: Texas IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 140: Florida IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 141: Georgia IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 142: North Carolina IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 143: Tennessee IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 144: South Carolina IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 145: Alabama IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 146: Mississippi IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 147: Louisiana IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 148: Arkansas IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 149: Kentucky IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 150: Oklahoma IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 151: Virginia IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 152: Maryland IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 153: West Virginia IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 154: Midwest Region U.S. IVD Test Kits Market: Regional Overview and Trends
TABLE 155: Midwest Region U.S. IVD Test Kits Market: Key Manufacturers, Laboratories and Distribution Ecosystem
TABLE 156: Midwest Region U.S. IVD Test Kits Market, by State, 2021–2035 (US$ Billion)
TABLE 157: Midwest Region U.S. IVD Test Kits Market, by Product Format, 2021–2035 (US$ Billion)
TABLE 158: Midwest Region U.S. IVD Test Kits Market, by Technology, 2021–2035 (US$ Billion)
TABLE 159: Midwest Region U.S. IVD Test Kits Market, by Application, 2021–2035 (US$ Billion)
TABLE 160: Midwest Region U.S. IVD Test Kits Market, by Sample Type, 2021–2035 (US$ Billion)
TABLE 161: Midwest Region U.S. IVD Test Kits Market, by End User, 2021–2035 (US$ Billion)
TABLE 162: Illinois IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 163: Ohio IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 164: Michigan IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 165: Minnesota IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 166: Indiana IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 167: Wisconsin IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 168: Missouri IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 169: Iowa IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 170: Kansas IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 171: Nebraska IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 172: North Dakota IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 173: South Dakota IVD Test Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 174: U.S. IVD Test Kits Market: Competitive Landscape Snapshot, 2025
TABLE 175: U.S. IVD Test Kits Market: Key Company Market Share Analysis, 2025
TABLE 176: U.S. IVD Test Kits Market: Company Positioning Matrix
TABLE 177: U.S. IVD Test Kits Market: Assay Portfolio Benchmarking of Key Players
TABLE 178: U.S. IVD Test Kits Market: Molecular, Point-of-Care and Home Testing Competitive Benchmarking
TABLE 179: U.S. IVD Test Kits Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 180: Roche Diagnostics: Company Profile
TABLE 181: Abbott Laboratories: Company Profile
TABLE 182: Danaher Corporation: Company Profile
TABLE 183: Siemens Healthineers: Company Profile
TABLE 184: Becton, Dickinson and Company: Company Profile
TABLE 185: bioMérieux: Company Profile
TABLE 186: Bio-Rad Laboratories: Company Profile
TABLE 187: QuidelOrtho Corporation: Company Profile
TABLE 188: Hologic, Inc.: Company Profile
TABLE 189: QIAGEN: Company Profile
TABLE 190: Thermo Fisher Scientific: Company Profile
TABLE 191: DiaSorin: Company Profile
TABLE 192: Revvity: Company Profile
TABLE 193: Sysmex Corporation: Company Profile
TABLE 194: Werfen: Company Profile
TABLE 195: Grifols: Company Profile
TABLE 196: Sekisui Diagnostics: Company Profile
TABLE 197: Meridian Bioscience: Company Profile
TABLE 198: Fujirebio Diagnostics: Company Profile
TABLE 199: Trinity Biotech: Company Profile
TABLE 200: OraSure Technologies: Company Profile
TABLE 201: Seegene Technologies: Company Profile
TABLE 202: Healgen Scientific: Company Profile
TABLE 203: iHealth Labs: Company Profile
TABLE 204: Exact Sciences Corporation: Company Profile
TABLE 205: U.S. IVD Test Kits Market: Future Market Scenario Analysis, 2026–2035
TABLE 206: U.S. IVD Test Kits Market: Disruptive Technologies Impact Matrix
TABLE 207: U.S. IVD Test Kits Market: Multiplex Molecular Diagnostics Opportunity Analysis
TABLE 208: U.S. IVD Test Kits Market: Digital PCR and High-Sensitivity Testing Opportunity Analysis
TABLE 209: U.S. IVD Test Kits Market: Home Testing and Self-Collection Growth Outlook
TABLE 210: U.S. IVD Test Kits Market: Emerging Business Trends
TABLE 211: U.S. IVD Test Kits Market: Business Opportunities for Startups and Existing Players
TABLE 212: U.S. IVD Test Kits Market: Investment Prioritization Matrix
TABLE 213: U.S. IVD Test Kits Market: Strategic Recommendations for IVD Test Kit Manufacturers
TABLE 214: U.S. IVD Test Kits Market: Strategic Recommendations for Hospital and Health System Laboratories
TABLE 215: U.S. IVD Test Kits Market: Strategic Recommendations for Independent and Reference Laboratories
TABLE 216: U.S. IVD Test Kits Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 217: U.S. IVD Test Kits Market: Strategic Recommendations for Distributors and Channel Partners
TABLE 218: U.S. IVD Test Kits Market: Strategic Recommendations for New Entrants and Diagnostic Startups
TABLE 219: U.S. IVD Test Kits Market: Go-to-Market Strategy Considerations
TABLE 220: U.S. IVD Test Kits Market: Product Positioning and Assay Portfolio Expansion Guidance
TABLE 221: U.S. IVD Test Kits Market: Molecular Diagnostics Commercialization Strategy
TABLE 222: U.S. IVD Test Kits Market: Point-of-Care and CLIA-Waived Market Entry Strategy
TABLE 223: U.S. IVD Test Kits Market: Home Testing and Consumer Diagnostics Strategy
TABLE 224: U.S. IVD Test Kits Market: Reimbursement and Evidence Generation Strategy
TABLE 225: U.S. IVD Test Kits Market: Scope Limitation
TABLE 226: U.S. IVD Test Kits Market: Data Use Limitation
TABLE 227: U.S. IVD Test Kits Market: Forecasting Limitation
TABLE 228: U.S. IVD Test Kits Market: Legal Disclaimer
TABLE 229: U.S. IVD Test Kits Market: Third-Party Data Disclaimer
TABLE 230: U.S. IVD Test Kits Market: Regulatory and Reimbursement Data Limitation

List of Figures

FIGURE 1: U.S. IVD Test Kits Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: U.S. IVD Test Kits Market Ecosystem
FIGURE 4: U.S. IVD Test Kits Market Stakeholder Framework
FIGURE 5: U.S. IVD Test Kits Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 6: U.S. IVD Test Kits Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 7: U.S. IVD Test Kits Market Year-wise Growth Curve, 2021–2035
FIGURE 8: COVID-Era Testing Demand Normalization Curve, 2021–2025
FIGURE 9: Market Attractiveness Analysis
FIGURE 10: Market Dynamics
FIGURE 11: Innovation & Patent Landscape, 2021–2025
FIGURE 12: Clinical Laboratory Workflow Economics Framework
FIGURE 13: Cost per Reportable Result Framework
FIGURE 14: Laboratory Assay Procurement Decision Framework
FIGURE 15: Decentralized and Point-of-Care Testing Adoption Roadmap
FIGURE 16: Home Testing and Self-Collection Opportunity Map
FIGURE 17: PESTEL Analysis
FIGURE 18: Porter’s Five Forces Analysis
FIGURE 19: Value Chain Analysis
FIGURE 20: Supply Chain Analysis
FIGURE 21: FDA IVD Regulatory Pathway Framework
FIGURE 22: CLIA Testing Complexity and Waiver Framework
FIGURE 23: CMS Clinical Laboratory Reimbursement Framework
FIGURE 24: U.S. IVD Test Kits Innovation Landscape
FIGURE 25: Product Format Segment Market Share Analysis, 2025 & 2035
FIGURE 26: Product Format Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 27: Reagent and Assay Kits Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 28: Molecular Diagnostic Cartridges and Closed-System Kits Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 29: Rapid Cassette and Lateral-Flow Test Kits Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 30: Test Strips and Dipstick-Based Kits Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 31: Self-Test and Integrated Home Testing Kits Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 32: Technology Segment Market Share Analysis, 2025 & 2035
FIGURE 33: Technology Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 34: Immunoassay Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 35: Molecular Diagnostics Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 36: Clinical Chemistry Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 37: Hematology and Coagulation Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 38: Microbiology, Urinalysis and Other Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 39: Application Segment Market Share Analysis, 2025 & 2035
FIGURE 40: Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 41: Infectious Diseases Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 42: Oncology Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 43: Diabetes and Cardiometabolic Disorders Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 44: Women’s Health, Reproductive Health and Sexual Health Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 45: Endocrine, Autoimmune, Gastrointestinal, Renal and Other Applications Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 46: Sample Type Segment Market Share Analysis, 2025 & 2035
FIGURE 47: Sample Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 48: Blood, Serum and Plasma Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 49: Respiratory Swabs and Saliva Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 50: Urine Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 51: Stool Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 52: Tissue, Cytology and Other Specimens Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 53: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 54: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 55: Hospital and Health System Laboratories Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 56: Independent and Reference Laboratories Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 57: Physician Offices, Urgent Care Centers and Retail Clinics Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 58: Public Health Laboratories, Blood Banks and Community Testing Programs Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 59: Home and Consumer Testing Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 60: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 61: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 62: U.S. Regional CLIA Laboratory and Diagnostic Testing Infrastructure Map
FIGURE 63: West Region U.S. IVD Test Kits Market Share and Leading Players, 2025
FIGURE 64: West Region Market Share Analysis by State, 2025
FIGURE 65: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 66: California IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 67: Washington IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 68: Arizona IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 69: Colorado IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 70: Oregon IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 71: Utah IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 72: Nevada IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 73: New Mexico IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 74: Idaho IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 75: Montana IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 76: Wyoming IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 77: Alaska IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 78: Hawaii IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 79: Northeast Region U.S. IVD Test Kits Market Share and Leading Players, 2025
FIGURE 80: Northeast Region Market Share Analysis by State, 2025
FIGURE 81: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 82: New York IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 83: Massachusetts IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 84: New Jersey IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 85: Pennsylvania IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 86: Connecticut IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 87: Maine IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 88: Vermont IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 89: New Hampshire IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 90: Rhode Island IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 91: Delaware IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 92: South Region U.S. IVD Test Kits Market Share and Leading Players, 2025
FIGURE 93: South Region Market Share Analysis by State, 2025
FIGURE 94: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 95: Texas IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 96: Florida IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 97: Georgia IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 98: North Carolina IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 99: Tennessee IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 100: South Carolina IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 101: Alabama IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 102: Mississippi IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 103: Louisiana IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 104: Arkansas IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 105: Kentucky IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 106: Oklahoma IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 107: Virginia IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 108: Maryland IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 109: West Virginia IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 110: Midwest Region U.S. IVD Test Kits Market Share and Leading Players, 2025
FIGURE 111: Midwest Region Market Share Analysis by State, 2025
FIGURE 112: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 113: Illinois IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 114: Ohio IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 115: Michigan IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 116: Minnesota IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 117: Indiana IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 118: Wisconsin IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 119: Missouri IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 120: Iowa IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 121: Kansas IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 122: Nebraska IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 123: North Dakota IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 124: South Dakota IVD Test Kits Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 125: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 126: Company Positioning Matrix
FIGURE 127: Key Player Assay Portfolio Benchmarking
FIGURE 128: Molecular Diagnostics Competitive Positioning Matrix
FIGURE 129: Point-of-Care and Home Testing Competitive Positioning
FIGURE 130: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 131: U.S. IVD Test Kits Innovation Roadmap
FIGURE 132: Multiplex Molecular Diagnostics Adoption Roadmap
FIGURE 133: Digital PCR and High-Sensitivity Diagnostics Opportunity Map
FIGURE 134: Home Testing and Self-Collection Growth Roadmap
FIGURE 135: Oncology and Companion Diagnostics Opportunity Map
FIGURE 136: Future Market Scenario Analysis, 2026–2035
FIGURE 137: Disruptive Technologies Impact Matrix
FIGURE 138: Emerging Business Trends Matrix
FIGURE 139: Investment Prioritization Matrix
FIGURE 140: High-Growth Application Opportunity Matrix
FIGURE 141: Future Laboratory Workflow Transformation Roadmap
FIGURE 142: Strategic Growth Roadmap for U.S. IVD Test Kit Manufacturers
FIGURE 143: Go-to-Market Strategy Framework
FIGURE 144: Product Positioning and Assay Portfolio Expansion Framework
FIGURE 145: Molecular Diagnostics Commercialization Framework
FIGURE 146: Point-of-Care and CLIA-Waived Market Entry Framework
FIGURE 147: Home and Consumer Diagnostics Strategy Framework
FIGURE 148: Reimbursement and Evidence Generation Framework
FIGURE 149: Laboratory Contracting and Installed-Base Strategy Framework
FIGURE 150: Report Scope and Disclaimer Framework